Mitralign, a Tewksbury, MA firm, won European regulatory approval to introduce the Mitralign Percutaneous Annuloplasty System (MPAS) for repair of functional mitral regurgitation. The Mitralign system offers a minimally invasive ability for physicians to slightly reshape the mitral annulus, resulting in a more narrow opening that reduces the amount of backflow, effectively helping to treat the condition.
From the announcement:
Data from the CE mark study demonstrated the Mitralign System met both its 30 day safety and its six month performance endpoints. In the prospective, multi-center, single arm study, patients treated with the Mitralign System demonstrated statistically significant (p<0.05) improvements in 6 minute walk test, left ventricular dimensions and remodeling; reversing the course of heart dilation due to heart failure.
Here’s a great animation explaining the workings of the Mitralign procedure: